NOVN.CH

127.1

-0.72%↓

LONN.CH

520.2

-0.42%↓

STMN.CH

88.94

+0.72%↑

NOVN.CH

127.1

-0.72%↓

LONN.CH

520.2

-0.42%↓

STMN.CH

88.94

+0.72%↑

NOVN.CH

127.1

-0.72%↓

LONN.CH

520.2

-0.42%↓

STMN.CH

88.94

+0.72%↑

NOVN.CH

127.1

-0.72%↓

LONN.CH

520.2

-0.42%↓

STMN.CH

88.94

+0.72%↑

NOVN.CH

127.1

-0.72%↓

LONN.CH

520.2

-0.42%↓

STMN.CH

88.94

+0.72%↑

Home・Akcijų sąrašas・Roche Holding AG

Roche Holding AG

Atidarymo kaina

SektoriusSveikatos priežiūra

370.8 1.26

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

362.8

Max

369.6

Pagrindiniai rodikliai
By Trading Economics
Pajamos	1.8B 5.5B
Pardavimai	15B 31B
P/E Sektoriaus vid.	23.041 108.767
Dividendų pajamingumas	2.63
Pelno marža	17.892
Darbuotojai	103,249
EBITDA	5.1B 12B

Dividendai
By Dow Jones
Dividendų pajamingumas Sektoriaus vid.	2.63% 2.21%

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	5.3B 294B
Ankstesnė atidarymo kaina	369.54
Ankstesnė uždarymo kaina	370.8

Naujienos nuotaikos

By Acuity

100%

333 / 352 reitingas Healthcare

Roche Holding AG Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-01-29 10:07; UTC

Uždarbis

Roche Forecasts 2026 Growth, Cites Drug-Pipeline Strength -- Update

2026-01-29 07:07; UTC

Uždarbis

Roche Forecasts 2026 Growth, Helped by Strength of Drug Pipeline

2025-11-18 11:04; UTC

Pagrindinės rinkos jėgos

Roche Shares Rise After Breast-Cancer Pill Shows Positive Results in Trial

2025-10-23 09:32; UTC

Uždarbis

Roche Raises Full-Year Earnings Outlook as U.S. Drug-Pricing Talks Continue -- Update

2025-10-23 05:54; UTC

Uždarbis

Roche Raises Full-Year Earnings Outlook

2026-03-03 07:22; UTC

Rinkos pokalbiai

Roche's Multiple Sclerosis Drug Safety Remains in Focus After Latest Trial -- Market Talk

2026-03-02 14:21; UTC

Rinkos pokalbiai

Roche's Multiple Sclerosis Drug Might Not Clear FDA Bar -- Market Talk

2026-01-29 11:40; UTC

Rinkos pokalbiai

Uždarbis

Roche's Guidance Seems Less Conservative Than Expected -- Market Talk

2026-01-29 06:05; UTC

Uždarbis

Roche Expects 2026 Core EPS to Increase in High-Single Digit Range at CER

2026-01-29 06:04; UTC

Uždarbis

Roche Expects 2026 Mid-Single-Digit Range Sales Increase at Constant Currency

2026-01-29 06:03; UTC

Uždarbis

Roche Issues 2026 View

2026-01-29 06:02; UTC

Uždarbis

Analysts Saw 2025 Core EPS at CHF19.70

2026-01-29 06:02; UTC

Uždarbis

Roche: 2025 Core EPS CHF19.46

2026-01-29 06:01; UTC

Uždarbis

Analysts Had Seen 2025 Sales At CHF61.47B

2026-01-29 06:01; UTC

Uždarbis

Roche 2025 Sales CHF61.52B

2026-01-28 11:22; UTC

Uždarbis

Roche's Prospects in Weight-Loss Field to be in Focus -- Earnings Preview

2026-01-27 11:31; UTC

Rinkos pokalbiai

Roche's Weight-Loss Study Results Seem Promising -- Market Talk

2026-01-27 11:24; UTC

Rinkos pokalbiai

Roche Might Struggle to Leave Mark in Crowded Obesity Market With CT-388 -- Market Talk

2026-01-27 09:30; UTC

Rinkos pokalbiai

Roche's CT-388 Could Compete With Lilly's Zepbound on Obesity Efficacy -- Market Talk

2026-01-27 07:52; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Roche Obesity Study Data Look Encouraging -- Market Talk

2026-01-16 17:03; UTC

Rinkos pokalbiai

All Eyes on Guidance for European Big Pharma Earnings Season -- Market Talk

2026-01-12 14:50; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Pharma Sector Can Spend Big on M&A -- Market Talk

2025-12-22 08:48; UTC

Rinkos pokalbiai

U.S. Administration's Deals With Big Pharma Unveil Pricing Uncertainty -- Market Talk

2025-11-19 12:47; UTC

Rinkos pokalbiai

Roche's Breast Cancer Drug Trial Results Surprise Positively -- Market Talk

2025-11-10 12:16; UTC

Rinkos pokalbiai

Uždarbis

Roche Results for MS-Treatment Candidate Look Encouraging -- Market Talk

2025-10-23 09:19; UTC

Rinkos pokalbiai

Uždarbis

Roche's Sales Slow, But Drug Pipeline Could Support Long-Term Growth -- Market Talk

2025-10-23 09:11; UTC

Rinkos pokalbiai

Uždarbis

Roche Sales Miss Driven by Underperformance of Key Drugs -- Market Talk

2025-10-23 05:09; UTC

Uždarbis

Roche 3Q Sales Up 6% At CER

2025-10-23 05:07; UTC

Uždarbis

Roche 3Q Sales CHF14.92B

2025-10-23 05:07; UTC

Uždarbis

Analysts Had Seen 3Q Sales At CHF15.17B

Akcijų palyginimas

Kainos pokytis

Roche Holding AG Prognozė

Bendras įvertinimas

By TipRanks

0 ratings

Pirkti

Laikyti

Parduoti

Remiantis 0 analitikų, pateikusių Roche Holding AG akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Rinkos nuotaikos

By Acuity

333 / 352 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Roche Holding AG

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It is also developing products for various therapeutic areas. In addition, it offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases; diagnostic instruments; and digital health solutions. It has strategic discovery collaboration with Flare Therapeutics Inc. proteomic and mass spectrometry platform and expertise to discover novel small molecules aimed at transcription factor targets in oncology. Roche Holding AG was founded in 1896 and is based in Basel, Switzerland.